Liberty Wealth Management LLC Reduces Holdings in Gilead Sciences, Inc. $GILD

Liberty Wealth Management LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,972 shares of the biopharmaceutical company’s stock after selling 318 shares during the quarter. Liberty Wealth Management LLC’s holdings in Gilead Sciences were worth $219,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the 1st quarter worth approximately $25,000. Activest Wealth Management increased its holdings in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. GoalVest Advisory LLC increased its holdings in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences in the second quarter worth $27,000. Finally, Colonial Trust Advisors increased its stake in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 213 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the transaction, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This represents a 1.66% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,500 shares of company stock worth $7,142,140 in the last three months. 0.27% of the stock is owned by insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $120.47 on Tuesday. The company has a market cap of $149.48 billion, a PE ratio of 24.00, a P/E/G ratio of 0.83 and a beta of 0.34. The firm has a 50-day simple moving average of $115.52 and a 200 day simple moving average of $111.21. Gilead Sciences, Inc. has a fifty-two week low of $86.08 and a fifty-two week high of $124.61. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on GILD. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $105.00 to $108.00 and gave the stock a “neutral” rating in a research report on Friday, October 17th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a research report on Tuesday, August 19th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada boosted their price target on Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $122.61.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.